Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients. response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue in clinical oncology. and the identification of new targets and combination therapies is... https://www.protectoracarballo.com/product-category/denim/